Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETON NASDAQ:FATE NASDAQ:KOD NASDAQ:TECX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETONEton Pharmaceuticals$17.67-1.1%$15.73$4.52▼$21.48$473.87M1.1285,878 shs286,782 shsFATEFate Therapeutics$1.01+3.8%$1.11$0.66▼$4.20$116.48M2.211.49 million shs1.66 million shsKODKodiak Sciences$10.52+23.0%$7.29$1.92▼$11.60$555.69M2.45634,630 shs786,870 shsTECXTectonic Therapeutic$16.80-2.7%$22.32$13.70▼$61.07$314.36M3.42409,456 shs683,688 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETONEton Pharmaceuticals0.00%+2.08%+15.79%+4.93%+283.30%FATEFate Therapeutics0.00%-2.88%+3.05%-36.88%-71.31%KODKodiak Sciences0.00%+16.37%+28.29%+149.29%+334.71%TECXTectonic Therapeutic0.00%-34.22%-23.36%-27.15%-12.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETONEton Pharmaceuticals$17.67-1.1%$15.73$4.52▼$21.48$473.87M1.1285,878 shs286,782 shsFATEFate Therapeutics$1.01+3.8%$1.11$0.66▼$4.20$116.48M2.211.49 million shs1.66 million shsKODKodiak Sciences$10.52+23.0%$7.29$1.92▼$11.60$555.69M2.45634,630 shs786,870 shsTECXTectonic Therapeutic$16.80-2.7%$22.32$13.70▼$61.07$314.36M3.42409,456 shs683,688 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETONEton Pharmaceuticals0.00%+2.08%+15.79%+4.93%+283.30%FATEFate Therapeutics0.00%-2.88%+3.05%-36.88%-71.31%KODKodiak Sciences0.00%+16.37%+28.29%+149.29%+334.71%TECXTectonic Therapeutic0.00%-34.22%-23.36%-27.15%-12.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETONEton Pharmaceuticals 3.00Buy$29.6767.89% UpsideFATEFate Therapeutics 2.14Hold$3.30226.73% UpsideKODKodiak Sciences 2.00Hold$11.7511.69% UpsideTECXTectonic Therapeutic 3.14Buy$80.29377.89% UpsideCurrent Analyst Ratings BreakdownLatest FATE, TECX, KOD, and ETON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025TECXTectonic TherapeuticOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$80.008/18/2025KODKodiak SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$3.00 ➝ $5.008/14/2025KODKodiak SciencesBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderweight$4.00 ➝ $7.008/14/2025KODKodiak SciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$15.008/13/2025FATEFate TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$4.00 ➝ $2.507/21/2025TECXTectonic TherapeuticTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$64.006/12/2025FATEFate TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold6/11/2025TECXTectonic TherapeuticRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$76.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETONEton Pharmaceuticals$39.01M12.15N/AN/A$0.94 per share18.80FATEFate Therapeutics$13.63M8.55N/AN/A$2.80 per share0.36KODKodiak SciencesN/AN/AN/AN/A$2.86 per shareN/ATECXTectonic TherapeuticN/AN/AN/AN/A$9.54 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETONEton Pharmaceuticals-$3.82M-$0.16N/A35.34N/A-7.10%-0.73%-0.22%11/11/2025 (Estimated)FATEFate Therapeutics-$186.26M-$1.45N/AN/AN/A-2,025.05%-50.95%-36.76%11/11/2025 (Estimated)KODKodiak Sciences-$176.21M-$3.80N/AN/AN/AN/A-155.27%-63.29%11/13/2025 (Estimated)TECXTectonic Therapeutic-$57.98M-$4.04N/AN/AN/AN/A-30.13%-28.33%11/6/2025 (Estimated)Latest FATE, TECX, KOD, and ETON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025KODKodiak Sciences-$1.01-$1.03-$0.02-$1.03N/AN/A8/12/2025Q2 2025FATEFate Therapeutics-$0.35-$0.29+$0.06-$0.29$1.16 million$1.91 million8/7/2025Q2 2025ETONEton Pharmaceuticals-$0.01-$0.10-$0.09-$0.10$16.71 million$18.93 million8/7/2025Q2 2025TECXTectonic Therapeutic-$0.98-$1.07-$0.09-$1.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthETONEton PharmaceuticalsN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETONEton Pharmaceuticals1.141.771.16FATEFate TherapeuticsN/A8.048.04KODKodiak SciencesN/A3.483.48TECXTectonic TherapeuticN/A25.6025.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETONEton Pharmaceuticals27.86%FATEFate Therapeutics97.54%KODKodiak Sciences89.06%TECXTectonic Therapeutic62.63%Insider OwnershipCompanyInsider OwnershipETONEton Pharmaceuticals16.03%FATEFate Therapeutics5.51%KODKodiak Sciences45.90%TECXTectonic Therapeutic38.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETONEton Pharmaceuticals2026.82 million22.52 millionOptionableFATEFate Therapeutics550115.33 million108.98 millionOptionableKODKodiak Sciences9052.82 million28.58 millionOptionableTECXTectonic Therapeutic12018.71 million11.60 millionN/AFATE, TECX, KOD, and ETON HeadlinesRecent News About These CompaniesEcoR1 Capital LLC Raises Stock Position in Tectonic Therapeutic, Inc. $TECXSeptember 6 at 8:27 AM | marketbeat.comTectonic Therapeutic (NASDAQ:TECX) Now Covered by Analysts at OppenheimerSeptember 6 at 3:45 AM | americanbankingnews.comTectonic Therapeutic (NASDAQ:TECX) Coverage Initiated at OppenheimerSeptember 5 at 9:44 AM | marketbeat.com132,222 Shares in Tectonic Therapeutic, Inc. $TECX Bought by Ally Bridge Group NY LLCSeptember 5 at 6:54 AM | marketbeat.com5AM Venture Management LLC Cuts Holdings in Tectonic Therapeutic, Inc. $TECXSeptember 4 at 7:52 AM | marketbeat.comBaker BROS. Advisors LP Invests $1.77 Million in Tectonic Therapeutic, Inc. $TECXSeptember 4 at 6:39 AM | marketbeat.comOppenheimer Initiates Coverage of Tectonic Therapeutic (TECX) with Outperform RecommendationSeptember 4 at 5:37 AM | msn.com21,126 Shares in Tectonic Therapeutic, Inc. $TECX Acquired by Jump Financial LLCSeptember 4 at 3:56 AM | marketbeat.comTectonic Therapeutic initiated with an Outperform at OppenheimerSeptember 3, 2025 | msn.comTectonic Stock Soars Pre-market After Tuesday’s Sell-Off: Oppenheimer Is Hopeful About Company’s Lead CandidateSeptember 3, 2025 | msn.comWellington Management Group LLP Invests $348,000 in Tectonic Therapeutic, Inc. $TECXSeptember 3, 2025 | marketbeat.comTectonic Therapeutic to Participate in September Investor ConferencesAugust 28, 2025 | globenewswire.comTectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Recommendation of "Buy" from BrokeragesAugust 24, 2025 | marketbeat.com15,369 Shares in Tectonic Therapeutic, Inc. $TECX Acquired by Cliffwater LLCAugust 20, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Has $614,000 Stock Position in Tectonic Therapeutic, Inc. $TECXAugust 20, 2025 | marketbeat.com40,000 Shares in Tectonic Therapeutic, Inc. (NASDAQ:TECX) Bought by Knott David M JrAugust 12, 2025 | marketbeat.comTectonic Therapeutic (NASDAQ:TECX) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPSAugust 11, 2025 | marketbeat.comTectonic Therapeutic Reports Q2 Financial ResultsAugust 9, 2025 | theglobeandmail.comTectonic (TECX) Q2 R&D Soars 142%August 7, 2025 | fool.comTectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 7, 2025 | manilatimes.netMTectonic Therapeutic (TECX) to Release Quarterly Earnings on WednesdayAugust 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFATE, TECX, KOD, and ETON Company DescriptionsEton Pharmaceuticals NASDAQ:ETON$17.67 -0.20 (-1.12%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$17.72 +0.05 (+0.31%) As of 09/5/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Fate Therapeutics NASDAQ:FATE$1.01 +0.04 (+3.81%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.00 -0.01 (-0.50%) As of 09/5/2025 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Kodiak Sciences NASDAQ:KOD$10.52 +1.97 (+23.04%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$10.44 -0.07 (-0.71%) As of 09/5/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Tectonic Therapeutic NASDAQ:TECX$16.80 -0.47 (-2.72%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$16.90 +0.10 (+0.59%) As of 09/5/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
